Share-based Payment Arrangement, Expense of Verve Therapeutics, Inc. from 31 Dec 2019 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Verve Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 31 Mar 2025.
  • Verve Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $11,174,000, a 8.1% increase year-over-year.
  • Verve Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $44,088,000, a 18% increase year-over-year.
  • Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $43,255,000, a 23% increase from 2023.
  • Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $35,116,000, a 56% increase from 2022.
  • Verve Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $22,477,000, a 218% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Verve Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $44,088,000 $11,174,000 +$833,000 +8.1% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $43,255,000 $10,449,000 +$1,195,000 +13% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $42,060,000 $10,818,000 +$1,993,000 +23% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $40,067,000 $11,647,000 +$2,634,000 +29% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $37,433,000 $10,341,000 +$2,317,000 +29% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $35,116,000 $9,254,000 +$2,549,000 +38% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $32,567,000 $8,825,000 +$2,905,000 +49% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $29,662,000 $9,013,000 +$3,364,000 +60% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $26,298,000 $8,024,000 +$3,821,000 +91% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $22,477,000 $6,705,000 +$3,947,000 +143% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $18,530,000 $5,920,000 +$3,627,000 +158% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $14,903,000 $5,649,000 +$4,298,000 +318% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $10,605,000 $4,203,000 +$3,533,000 +527% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $7,072,000 $2,758,000 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $2,293,000 +$2,080,000 +977% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $1,351,000 +$1,251,000 +1251% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $670,000 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q3 2020 $213,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $100,000 01 Apr 2020 30 Jun 2020 10-Q/A 16 Aug 2021 2021 Q2

Verve Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $43,255,000 +$8,139,000 +23% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $35,116,000 +$12,639,000 +56% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $22,477,000 +$15,405,000 +218% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $7,072,000 +$6,222,000 +732% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $850,000 +$404,000 +91% 01 Jan 2020 31 Dec 2020 10-K 02 Mar 2023 2022 FY
2019 $446,000 01 Jan 2019 31 Dec 2019 10-K 14 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.